- Indication
- Metabolic acidosis in adults with chronic kidney disease
- RAG rating
- Amber initiation
- Document type
- Decision document
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Nephrotrans® (sodium hydrogen carbonate gastro-resistant 500mg capsules)
HERTFORDSHIRE AND WEST ESSEX AREA
PRESCRIBING COMMITTEE (HWE APC)
Nephrotrans® (sodium hydrogen
carbonate gastro-resistant 500mg capsules) for treatment and maintenance of
metabolic acidosis in adults with chronic kidney disease
AMBER INITIATION
Recommended for initiation by specialists, ongoing prescribing in primary care, following stabilisation of therapy, and after an assessment of tolerability and efficacy has been made by the specialists.
|
Name generic (trade):
|
Sodium hydrogen carbonate gastro-resistant 500mg
capsules
|
|
What it is:
|
Increases the body's pH level
|
|
Indication:
|
Licensed for the treatment of metabolic acidosis and
for maintenance treatment against recurrence of metabolic acidosis in adults
with chronic renal impairment.
|
|
Date decision last revised:
|
September 2024
|
|
NICE
|
NICE NG203 recommended
|
HWE APC recommendation:
Nephrotrans® (sodium hydrogen carbonate gastro-resistant
500mg capsules) recommended for restricted use as an option for treatment and
maintenance of metabolic acidosis in adults with chronic kidney disease in line
with NICE NG203 as second
line option when patients cannot tolerate first line option sodium bicarbonate
500mg capsules due to intolerable side effects such as bloating and wind
leading to discontinuation of treatment.
AMBER INITIATION:
- At initiation, specialists must also counsel the patient on all aspects related to the safe and effective use of this medication.
- During treatment, periodic check-ups must be carried out according to standard clinical practice.
Further information: for latest updates and more detailed information, including contra-indications, cautions and special warnings; please refer to summary of product characteristics SPC)
Note: Sodium bicarbonate 600mg tablets NOT recommended for new patients for treatment and maintenance of metabolic acidosis in chronic kidney disease. DOUBLE RED status: Not recommended for initiation by either Community, Secondary Tertiary or Primary Care. For existing patients, primary care may consider switching from sodium bicarbonate 600mg tablets to sodium bicarbonate 500mg capsules or sodium hydrogen carbonate gastro-resistant 500mg capsules (Nephrotrans®) if previous intolerance to standard capsules (see below) seeking advice and guidance from specialist team to support clinical decision making as appropriate. On the advice of local specialists switching between sodium bicarbonate formulations is a 1:1 switch with no additional monitoring required.
- Version number
- 1.0
- Developed by
- HWE ICB Pharmacy Medicines Optimisation Team
- Approved by
- HWE ICB Area Prescribing Committee
- Date approved / updated
- September 2024
- Review date
- The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
- Superseded version